Skip to main content
OpenTrials
Completed

NCT Number: NCT04252690

Physiological Study to Assess Mechanism of Action of MOBIDERM® in Lower-limb Lymphedema Patients

MOBIDERM® demonstrated his interest through clinical studies on the treatment of lower or upper limb lymphedema (Mestre et al 2017; Quéré et al. 2014). This CE (Conformity European)-marking device is well established both in ambulatory and hospitalisation. Nevertheless, the mechanism of action of this device had never been confirmed and no experimental clinical studies had been performed. The hypothesis is that the MOBIDERM system creates a pressure differential between the contact zone underneath the foam cubes composing the system and their surrounding area, leading to a shear effect on the subcutaneous tissues treated.

The aim of this study is thus to assess the mechanism of action of MOBIDERM on the lymphatic system by evaluating quantitative and qualitative effects of this medical device on lymphatic system, oedema volume and cutaneous parameters in 10 lymphoedema patients during their hospitalisation for reduction phase.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphedema of Leg Hemic and Lymphatic Diseases Lymphatic Diseases Lymphedema Lymphedema Congenital Lymphedema Primary Lymphedema, Secondary Neoplasm Metastasis Neoplasms Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHRU Tours

Tours, 37044, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Primary or secondary lower limb lymphedema of stage 2 or 3 according to the criteria defined by International Society of Lymphology
  • Affected leg that fits with one of the standard sizes of the Auto-Adjustable MOBIDERM® Autofit stocking provided
  • Signed informed consent prior to any study-mandated procedure.

Exclusion criteria

  • Pregnant or breastfeeding patient
  • Childbearing age patient without contraception
  • Intolerance to Mobiderm or known allergy to the components used
  • Evolutive lower limb infection
  • Acute lower limb inflammation
  • Dermatological ailment oozing from the treated limb
  • Severe medical condition that may interfere with the proper conduct of the study
  • Advanced diabetic microangiopathy
  • Limb arteritis stage III or IV
  • Decompensated heart failure
  • Involvement in another clinical study
  • Patient mentally incapable of understanding the nature, objectives and possible consequences of the study and / or refusing to submit to the constraints of this trial

Treatment and study plan

MOBIDERM® autofit : auto-adjustable compression stocking

Device

The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).

Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).

Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.

Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey).

Primary outcomes

  1. Change from baseline extraction rates at 3 days after wearing MOBIDERM

    Time frame: Day : 3

    Assess the difference of extraction rate (%) in different areas (ankle, upper and lower middle third of the leg, knee, calf) by lymphoscintigraphy performed at D1 and D3 after wearing MOBIDERM®

Secondary outcomes

  1. Change of vascular lymphatic activity between D1 and D3

    Time frame: Day : 3

    Assess change of vascular lymphatic activity based on qualitative data (activity YES/NO ; quality of activity : usual - semi usual - unusual) obtained during dynamic acquisition of lymphoscintigraphy from baseline to D3

  2. Change of lymphatic vascular flow between D1 and D3

    Time frame: Day : 3

    Assess change of amplitude vascular flow : important - medium- weak ; and of flow velocity : normal, slow, inexistent from baseline to D3

  3. Change on lymphatic system between D1 and D3 : short term effect

    Time frame: Day : 3

    Assess change on lymphatic system from baseline to D3 (short term effect) , based on quantitative data : number of lympho node fixation ; and qualitative data: lympho node fixation intensity : important - medium - low ; tortuous appearance of the lymphatic vessels : YES/NO ; presence of collateral : YES/NO ; presence of dermal reflux : YES/NO ; presence of popliteal ganglion : YES/NO.

  4. Change on lymphatic system between H2 and H4 : immediate effect

    Time frame: Hours : 2 and 4

    Assess change on lymphatic system from baseline to 2 and 4 hours : immediate effect, based on quantitative data : number of lympho node fixation ; and qualitative data: lympho node fixation intensity : important - medium - low ; tortuous appearance of the lymphatic vessels : YES/NO ; presence of collateral : YES/NO ; presence of dermal reflux : YES/NO ; presence of popliteal ganglion : YES/NO.

  5. Lymphedema volume reduction between D1 and D3

    Time frame: Days : 1 and 3

    Leg perimeters (cm) of 7 part of leg will be measured (ankle, patella, +10cm +20cm +30cm and -10cm -20cm and -30cm of patella). Based on truncated cone formula, volume (mL) of each leg will be calculated. These volumes will be compared between D1 and D3 in order to assess lymphedema volume reduction.

  6. Skin condition evolution between D1 and D3

    Time frame: Days : 1 and 3

    Skin condition will be assessed by cutaneous ultrasound scan (skin thickness (mm) , skin echogenicity (hypoechogenicity - isoechogenicity, hyperechogenicity) , oedema distribution in the dermis (superficial dermis - deep dermis - overall of dermis -hypodermis and dermis) performed on 3 areas : ankle, leg and thigh. Skin condition evolution will be assessed at D1 and D3.

  7. Cutaneous suppleness between D1 and D3

    Time frame: Days : 1 and 3

    Cutaneous suppleness evolution is assessed with a cutometer. Cutaneous suppleness is described by skin elasticity, elastic capacity and viscoelasticity. Cutometer measurements are expressed in millimetre (skin deformation, skin relaxation, skin extensibility) and will be presented as quantitative data.

  8. Number of type of serious and non-serious Adverse Device Effects

    Time frame: Day : 3

    Number and type of serious and non-serious Adverse Device Effects (ADE) will be reported during the study

  9. Satisfaction regarding MOBIDERM

    Time frame: Day : 3

    Satisfaction is measured by a satisfaction questionnaire wrote specifically for the study. This questionnaire is focused on positioning the product, comfort, esthetic and global satisfaction.

Sponsors and collaborators

Lead sponsor

Thuasne

Industry

Collaborators

  • Delta Consultants
  • University Hospital, Tours

Registry information

Acronym: ACTIODERM

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Feb 5, 2020
Registry last updated
Apr 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.